Repligen (NASDAQ:RGEN – Get Rating) updated its FY23 earnings guidance on Tuesday. The company provided earnings per share guidance of $2.35-$2.42 for the period, compared to the consensus earnings per share estimate of $2.64. The company issued revenue guidance of $720-$760 million, compared to the consensus revenue estimate of $779.97 million. Wall Street Analyst Weigh […]
Repligen (NASDAQ:RGEN – Get Rating) had its price objective dropped by research analysts at Royal Bank of Canada from $170.00 to $157.00 in a note issued to investors on Wednesday, The Fly reports. Royal Bank of Canada’s price target would suggest a potential downside of 3.20% from the stock’s previous close. A number of other […]
Repligen (NASDAQ:RGEN – Get Rating) had its price objective cut by Royal Bank of Canada from $170.00 to $157.00 in a research report issued on Wednesday, The Fly reports. Royal Bank of Canada’s target price indicates a potential downside of 3.20% from the company’s previous close. Several other research firms have also recently commented on […]
Repligen (NASDAQ:RGEN – Get Rating) had its price objective cut by research analysts at Benchmark from $230.00 to $210.00 in a research report issued on Wednesday, The Fly reports. Benchmark’s target price points to a potential upside of 33.56% from the stock’s previous close. A number of other equities research analysts also recently weighed in […]
Repligen (NASDAQ:RGEN – Get Rating) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.05, Briefing.com reports. The firm had revenue of $182.70 million for the quarter, compared to analyst estimates of $181.43 million. Repligen had a return on […]